Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

被引：42

作者：

Milovan, Denise ^{[2
]}

Almeida, Luis ^{[1
,3
]}

Romach, Myroslava K. ^{[2
]}

Nunes, Teresa ^{[1
]}

Rocha, Jose Francisco ^{[1
]}

Sokowloska, Marta ^{[2
]}

Sellers, Edward M. ^{[2
]}

Soares-da-Silva, Patricio ^{[1
,4
]}

机构：

[1] BIAL Portela & Co SA, Dept Res & Dev, Sao Mamede Do Coronado, Portugal

[2] Kendle Early Stage, Toronto, ON, Canada

[3] Univ Aveiro, Hlth Sci Sect, P-3800 Aveiro, Portugal

[4] Univ Porto, Fac Med, Inst Pharmacol & Therapeut, P-4100 Oporto, Portugal

来源：

EPILEPSY & BEHAVIOR | 2010年 / 18卷 / 04期

关键词：

Antiepileptic drugs; Cognition; Eslicarbazepine acetate; Oxcarbazepine; Psychomotor performance; PARTIAL-ONSET SEIZURES; ADJUNCTIVE TREATMENT; ANTIEPILEPTIC DRUGS; CARBAMAZEPINE; PHARMACOKINETICS; EFFICACY; DERIVATIVES; BIA-2-093; DIAZEPAM; SAFETY;

D O I：

10.1016/j.yebeh.2010.04.022

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

010107 [宗教学]; 030301 [社会学]; 070906 [古生物学及地层学（含古人类学）];

摘要：

The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported. The cognitive and psychomotor evaluation consisted of several computerized and paper-and-pencil measures. Eslicarbazepine acetate and oxcarbazepine had similar overall cognitive profiles and did not cause clinically relevant cognitive impairment The incidence of adverse events was lower with eslicarbazepine acetate than with oxcarbazepine. (C) 2010 Published by Elsevier Inc.

引用

页码：366 / 373

页数：8

共 30 条

[1]

Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects [J].

Almeida, L ;

Falcao, A ;

Maia, J ;

Mazur, D ;

Gellert, M ;

Soares-da-Silva, P .

JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) :1062-1066

[2]

Almeida L., 2009, TREATMENT EPILEPSY, P485

[3]

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment [J].

Almeida, Luis ;

Potgieter, J. Hendrick ;

Maia, Joana ;

Potgieter, M. Alida ;

Mota, Fernando ;

Soares-da-Silva, P. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) :267-273

[4]

Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024 [J].

Ambrósio, AF ;

Soares-da-Silva, P ;

Carvalho, CM ;

Carvalho, AP .

NEUROCHEMICAL RESEARCH, 2002, 27 (1-2) :121-130

[5]

Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons:: A comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093 [J].

Araújo, IM ;

Ambrósio, AF ;

Leal, EC ;

Verdasca, MJ ;

Malva, JO ;

Soares-Da-Silva, P ;

Carvalho, AP ;

Carvalho, CM .

EPILEPSIA, 2004, 45 (12) :1498-1505

[6]

Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives [J].

Benes, J ;

Parada, A ;

Figueiredo, AA ;

Alves, PC ;

Freitas, AP ;

Learmonth, DA ;

Cunha, RA ;

Garrett, J ;

Soares-da-Silva, P .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (14) :2582-2587

[7]

DIFFERENTIAL BEHAVIORAL EFFECTS IN FRONTAL LOBE DISEASE [J].

BENTON, AL .

NEUROPSYCHOLOGIA, 1968, 6 (01) :53-&

[8]

Bialer M., 2002, ANTIEPILEPTIC DRUGS, P459

[9]

PHARMACOLOGICAL EFFECTS AND ABUSE LIABILITY OF BRETAZENIL, DIAZEPAM, AND ALPRAZOLAM IN HUMANS [J].

BUSTO, U ;

KAPLAN, HL ;

ZAWERTAILO, L ;

SELLERS, EM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) :451-463

[10]

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study [J].

Elger, Christian ;

Halasz, Peter ;

Maia, Joana ;

Almeida, Luis ;

Soares-da-Silva, Patricio .

EPILEPSIA, 2009, 50 (03) :454-463

← 1 2 3 →